In 2017 and 2018, the Food and Drug Administration (FDA, USA) granted accelerated approvals for the PD‐1 inhibitors nivolumab and pembrolizumab in advanced HCC based on results from the CheckMate0405 and Keynote2246 trials, respectively. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.